Identification of dengue virus in Aedes mosquitoes and patients' sera from Si Sa Ket Province, Thailand.

Dengue fever (DF), dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS) are the re-emerging infectious diseases caused by dengue (DEN) virus, transmitted by Aedes mosquito. There are more than 100,000 cases of dengue infection and more than 100 deaths annually in Thailand. Virological surveillance for DEN viruses is used as an early warning system to predict outbreaks. The seroprevalence of infection and serotypes of DEN virus in 116 pediatric patients at Si Sa Ket Province, Thailand were analyzed during June to September 2004. At the same period, Aedes mosquitoes were caught from patients' and their neighbors' houses, from control houses, located in villages with no report of dengue infection during the previous 3 years. The majority of DHF cases were secondary infections of DEN-2 and DEN-4 serotypes. Of the 1,652 Aedes mosquitoes collected 1,583 were Ae. aegypti and 69 Ae. albopictus. Ten mosquitoes from each house were pooled and dengue viruses were determined using RT-PCR assay; only 1 positive pooled was found. Although the dengue infection rate in the field caught mosquitoes was low, the existing dengue virus control program in transmission areas by aerial spraying to destroy the larva breeding sites should be continued.

Neutralization titers against influenza A (H3N2) and influenza B viruses among a non-vaccinated population from Thailand.

Influenza A and B viruses are viral respiratory pathogens that can cause severe infections among birds and mammals. Neutralization assays using human sera are useful to evaluate the risk of circulating viruses to humans. In this study, 359 serum samples from healthy Thai volunteers, who had not been vaccinated against influenza for at least five years, were investigated by microneutralization (MN) assays against influenza A H3N2 and influenza B viruses in 2009. There was no significant difference in neutralization activities against 2006 and 2008 isolates of influenza A H3N2 viruses. However, neutralization titers to influenza B viruses among 2008 isolates were quite low. The results indicate the non-vaccinated study population had some neutralizing antibodies against influenza A H3N2 but not against influenza B viruses.

The serotype-independent but concentration-dependent enhancing antibodies among Thai dengue patients.

Antibody-dependent enhancement of infection (ADE) is central to explaining the development of severe disease at the end of post-dengue virus infection. Non-neutralizing anti-dengue antibodies bound to the dengue virion enhances the virus entrance into the target cells via the Fc receptor. The titer of enhancing antibodies in dengue patients is not determined during dengue virus infection. Sensitive flow cytometry detecting dengue virus-infected K562 cells was used to quantitate enhancing activity among Thai DF and DHF patients against four serotypes and the patient's dengue isolate. The titer was defined as the reciprocal of the final dilution that loses enhancing activity. The serum of Thai patients confirmed to have dengue infection were found to have high titers of enhancing antibodies and increased gradually through the convalescent phase of infection. The enhancing antibody titers were not different among the four serotypes or from the infecting isolate. The anti-dengue antibodies from dengue patients can enhance dengue virus infections in a concentration-dependent, serotype-independent manner.

Pharmacist involvement in primary care improves hypertensive patient clinical outcomes.

BACKGROUND: The practice of pharmaceutical care in primary care settings in Thailand is currently not generally accepted. OBJECTIVE: To evaluate the effect of pharmacist involvement in treatment with hypertensive patients in primary care settings. METHODS: The treatment objective was to stabilize the blood pressure (BP) of hypertensive patients in accordance with the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure guidelines. Patients were randomly assigned to a pharmacist-involved group (treatment) or a group with no pharmacist involvement (control). Pre- and post-test BPs, tablet counts, lifestyle modifications, and pharmacists' recommendations were recorded. The 6-month study was carried out in Mahasarakham University pharmacy and 2 primary care units. Patients were monitored monthly by reviewing their medications and supported by providing pharmaceutical care and counseling. RESULTS: From a total of 235 patients, the treatment group (n = 118) had a significant reduction in both systolic (S) and diastolic (D) BP compared with the 117 patients of the control group (p = 0.037, 0.027, respectively). The 158 patients (76 treatment, 82 control) with BPs >or=140/90 mm Hg at the beginning of the study showed significant BP reductions (p = 0.002 SBP, 0.008 DBP). The proportion of 158 patients whose BP became stabilized was higher in the treatment group (p = 0.017). The treatment group showed significantly better adherence (p = 0.014) and exercise control (p = 0.012) at the end of the study. Physicians accepted 42.72% of medication modifications and 5.34% of the suggestions for additional investigations. CONCLUSIONS: Hypertensive patients who received pharmacist input achieved a significantly greater benefit in BP reduction, BP control, and improvement in adherence rate and lifestyle modification.